RT Journal Article
SR Electronic
T1 SARS-CoV-2 virus dynamics in recently infected people – data from a household transmission study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.17.22272516
DO 10.1101/2022.03.17.22272516
A1 Mellis, Alexandra M.
A1 Meece, Jennifer K
A1 Halasa, Natasha B.
A1 Chappell, James D.
A1 McLean, Huong Q.
A1 Grijalva, Carlos G.
A1 Hanson, Kayla E.
A1 Zhu, Yuwei
A1 Kim, Ahra
A1 Deyoe, Jessica
A1 Ivacic, Lynn C.
A1 Reed, Carrie
A1 Talbot, H. Keipp
A1 Rolfes, Melissa A.
YR 2022
UL http://medrxiv.org/content/early/2022/03/18/2022.03.17.22272516.abstract
AB We used daily real-time reverse-transcription polymerase chain reaction (rRT-PCR) results from 67 cases of SARS-CoV-2 infection in a household transmission study to examine the trajectory of cycle threshold (Ct) values, an inverse correlate of viral RNA concentration, from nasal specimens collected between April 2020 and May 2021. Ct values varied over the course of infection, across RT-PCR platforms, and by participant age. Specimens collected from children and adolescents showed higher Ct values and adults aged ≥50 years showed lower Ct values than adults aged 18-49 years. Ct values were lower on days when participants reported experiencing symptoms.Competing Interest StatementDr. Grijalva reports grants from Campbell Alliance/Syneos, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from Pfizer, Merck, and Sanofi-Pasteur. Dr. Halasa reports grant support from Sanofi-Pasteur and Quidel.Funding StatementThis study was supported by the Centers for Disease Control and Prevention, (cooperative agreements IP001078 and IP001083). Dr. Grijalva was supported in part by the National Institute for Allergy and Infectious Diseases (K24 AI148459). The work used REDCap, which is supported by CTSA award No. UL1 TR002243 from the National Center for Advancing Translational Sciences (NCATS) Clinical Translational Science Award (CTSA) Program, Award Number 5UL1TR002243-03.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Institutional Review Boards at Vanderbilt University Medical Center and Marshfield Clinic Research Institute. CDC determined this activity was conducted consistent with applicable federal law and CDC policy (see 45 C.F.R. part 46; 21 C.F.R. part 56).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study may be available upon reasonable request to the authors.